NMD Pharma

Biotech · Aarhus, DK

ClC-1 chloride-channel inhibitors to restore muscle function in neuromuscular diseases

Founders

Thomas Holm Pedersen (Denmark · ♂) — A muscle-physiology researcher at Aarhus University who discovered that the ClC-1 muscle chloride channel could be targeted to restore neuromuscular transmission, then spun out NMD Pharma in 2015 to turn that science into treatments, serving as CEO.

Shares the most investors with (number = shared investors):

Create a free EquityFlow account to see NMD Pharma's 1 funding round, 5 investors, 12 similar companies.